Treace Does Not Issue 2026 Financial Guidance
The company said, "Treace is not issuing full-year 2026 guidance at this time, however, the Company anticipates continued positive procedure volume growth as well as the impact of previously disclosed dynamics, including headwinds related to broader economic conditions and softer consumer sentiment, as well as a product mix shift. The Company plans to provide 2026 financial guidance during its fourth quarter 2025 earnings conference call, which is currently scheduled for Thursday, February 26, 2026, at 4:30 p.m. Eastern Time."
Trade with 70% Backtested Accuracy
Analyst Views on TMCI
About TMCI
About the author
Treace Medical Concepts Reports Q4 2025 Revenue of $62.1M to $62.5M, Beating Consensus
- Revenue Performance: Treace Medical Concepts reported preliminary Q4 2025 revenue of $62.1M to $62.5M, reflecting a 9% decrease year-over-year, although it surpassed the consensus estimate of $61.76M, indicating ongoing business challenges.
- Annual Revenue Growth: For the full year 2025, preliminary revenue was $212.3M to $212.7M, representing a 2% increase compared to the previous year, aligning with the previously provided guidance of $211M to $213M, showcasing consistent growth amidst market conditions.
- Surgeon Increase: The company added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, a 6% increase from the prior year, indicating a 33% penetration rate among the estimated 10,000 U.S. surgeons performing bunion surgeries.
- Market Reaction: Treace Medical's stock rose 3.21% in pre-market trading to $2.89, reflecting investor optimism regarding the revenue beat, although the overall declining revenue trend remains a point of concern.
Treace Completes First Surgery Using Lapiplasty®Lightning™ Technology
- Technological Innovation: Treace Medical successfully completed the first surgery using its Lapiplasty®Lightning™ technology, which reduces surgical steps and enhances precision, thereby improving surgical efficiency and patient recovery times.
- Market Outlook: The company anticipates initiating a limited market release of the Lapiplasty®Lightning™ System in mid-2026, further driving Treace's market share in foot surgery to meet the growing surgical demand.
- Clinical Feedback: Surgeon William DeCarbo noted that the Lightning technology made the surgical process more intuitive, allowing for three-plane correction without the need for provisional fixation, thus streamlining the surgical workflow and enhancing patient safety.
- Industry Leadership: As a pioneer in 3D bunion correction, Treace solidifies its market leadership through continuous innovation, which is expected to attract more surgeons to adopt its advanced surgical systems.
Treace Medical CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Appearance: Treace Medical's CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 am PT, showcasing the company's innovations in foot surgery.
- Investor Relations: Treace encourages investors to regularly visit its website for important information that may impact investment decisions, demonstrating the company's commitment to transparency and investor communication.
- Market Potential: With approximately 67 million Americans affected by bunions, and an estimated 1.1 million surgical candidates annually, Treace's technology is poised to meet significant market demand and drive company growth.
- Technological Innovation: Treace's Lapiplasty®3D Bunion Correction System addresses the root cause of bunions, helping patients return to active lifestyles, reflecting the company's leadership in medical technology.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Johnson Fistel, PLLP Probes Allegations for Long-Term Investors in Quantum Computing Inc. (QUBT), Quanex Building Products Corporation (NX), Treace Medical Concepts, Inc. (TMCI), and BigBear.ai Holdings, Inc. (BBAI)
Investigation of Corporate Governance: Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by officers and directors of Quantum Computing Inc., Quanex Building Products Corporation, Treace Medical Concepts, and BigBear.ai Holdings, focusing on corporate governance reforms.
Quantum Computing Inc. Allegations: A securities class action complaint against Quantum Computing alleges misleading statements regarding its technology capabilities, relationships with NASA, and undisclosed related party transactions, which could negatively impact the company's reputation and business.
Quanex Building Products Allegations: The complaint against Quanex claims that the company made false statements about its maintenance practices in Mexico, leading to significant degradation of equipment and potential financial repercussions.
Treace Medical and BigBear.ai Allegations: Treace Medical faces allegations of failing to disclose competitive impacts on its primary product, while BigBear.ai is accused of maintaining deficient accounting practices that led to inaccurate financial statements and potential restatements.
UBS Keeps Neutral Rating on Treace Medical Concepts (TMCI)
UBS Coverage and Price Forecast: UBS has maintained a Neutral recommendation for Treace Medical Concepts (TMCI) as of November 7, 2025, with an average one-year price target of $8.67/share, indicating a potential upside of 94.39% from its current price of $4.46/share.
Projected Revenue and EPS: Treace Medical Concepts is projected to achieve annual revenue of $266 million, reflecting a 21.55% increase, while the expected non-GAAP EPS is -0.59.
Fund Sentiment and Ownership Changes: There are 257 funds reporting positions in TMCI, with a slight decrease in ownership by 3.02% over the last quarter. The average portfolio weight for these funds is 0.08%, which has increased by 1.55%.
Shareholder Activity: Notable changes in shareholder allocations include Armistice Capital increasing its stake by 0.78%, while CIBC Private Wealth Group and Jpmorgan Chase significantly reduced their holdings by 35.91% and 89.97%, respectively.
Treace Medical Concepts Reports Q4 2025 Revenue of $62.1M to $62.5M, Beating Consensus
- Revenue Performance: Treace Medical Concepts reported preliminary Q4 2025 revenue of $62.1M to $62.5M, reflecting a 9% decrease year-over-year, although it surpassed the consensus estimate of $61.76M, indicating ongoing business challenges.
- Annual Revenue Growth: For the full year 2025, preliminary revenue was $212.3M to $212.7M, representing a 2% increase compared to the previous year, aligning with the previously provided guidance of $211M to $213M, showcasing consistent growth amidst market conditions.
- Surgeon Increase: The company added approximately 202 new active surgeons in 2025, ending the year with around 3,337 active surgeons, a 6% increase from the prior year, indicating a 33% penetration rate among the estimated 10,000 U.S. surgeons performing bunion surgeries.
- Market Reaction: Treace Medical's stock rose 3.21% in pre-market trading to $2.89, reflecting investor optimism regarding the revenue beat, although the overall declining revenue trend remains a point of concern.
Treace Completes First Surgery Using Lapiplasty®Lightning™ Technology
- Technological Innovation: Treace Medical successfully completed the first surgery using its Lapiplasty®Lightning™ technology, which reduces surgical steps and enhances precision, thereby improving surgical efficiency and patient recovery times.
- Market Outlook: The company anticipates initiating a limited market release of the Lapiplasty®Lightning™ System in mid-2026, further driving Treace's market share in foot surgery to meet the growing surgical demand.
- Clinical Feedback: Surgeon William DeCarbo noted that the Lightning technology made the surgical process more intuitive, allowing for three-plane correction without the need for provisional fixation, thus streamlining the surgical workflow and enhancing patient safety.
- Industry Leadership: As a pioneer in 3D bunion correction, Treace solidifies its market leadership through continuous innovation, which is expected to attract more surgeons to adopt its advanced surgical systems.
Treace Medical CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- Conference Appearance: Treace Medical's CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 am PT, showcasing the company's innovations in foot surgery.
- Investor Relations: Treace encourages investors to regularly visit its website for important information that may impact investment decisions, demonstrating the company's commitment to transparency and investor communication.
- Market Potential: With approximately 67 million Americans affected by bunions, and an estimated 1.1 million surgical candidates annually, Treace's technology is poised to meet significant market demand and drive company growth.
- Technological Innovation: Treace's Lapiplasty®3D Bunion Correction System addresses the root cause of bunions, helping patients return to active lifestyles, reflecting the company's leadership in medical technology.
Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Johnson Fistel, PLLP Probes Allegations for Long-Term Investors in Quantum Computing Inc. (QUBT), Quanex Building Products Corporation (NX), Treace Medical Concepts, Inc. (TMCI), and BigBear.ai Holdings, Inc. (BBAI)
Investigation of Corporate Governance: Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by officers and directors of Quantum Computing Inc., Quanex Building Products Corporation, Treace Medical Concepts, and BigBear.ai Holdings, focusing on corporate governance reforms.
Quantum Computing Inc. Allegations: A securities class action complaint against Quantum Computing alleges misleading statements regarding its technology capabilities, relationships with NASA, and undisclosed related party transactions, which could negatively impact the company's reputation and business.
Quanex Building Products Allegations: The complaint against Quanex claims that the company made false statements about its maintenance practices in Mexico, leading to significant degradation of equipment and potential financial repercussions.
Treace Medical and BigBear.ai Allegations: Treace Medical faces allegations of failing to disclose competitive impacts on its primary product, while BigBear.ai is accused of maintaining deficient accounting practices that led to inaccurate financial statements and potential restatements.
UBS Keeps Neutral Rating on Treace Medical Concepts (TMCI)
UBS Coverage and Price Forecast: UBS has maintained a Neutral recommendation for Treace Medical Concepts (TMCI) as of November 7, 2025, with an average one-year price target of $8.67/share, indicating a potential upside of 94.39% from its current price of $4.46/share.
Projected Revenue and EPS: Treace Medical Concepts is projected to achieve annual revenue of $266 million, reflecting a 21.55% increase, while the expected non-GAAP EPS is -0.59.
Fund Sentiment and Ownership Changes: There are 257 funds reporting positions in TMCI, with a slight decrease in ownership by 3.02% over the last quarter. The average portfolio weight for these funds is 0.08%, which has increased by 1.55%.
Shareholder Activity: Notable changes in shareholder allocations include Armistice Capital increasing its stake by 0.78%, while CIBC Private Wealth Group and Jpmorgan Chase significantly reduced their holdings by 35.91% and 89.97%, respectively.
